{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["RNA interference technology", "age-related macular degeneration", "glaucoma", "non-viral vectors", "siRNA drugs"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "32298491", "DateCompleted": {"Year": "2021", "Month": "10", "Day": "04"}, "DateRevised": {"Year": "2021", "Month": "10", "Day": "04"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "05", "Day": "08"}], "Language": ["eng"], "ELocationID": ["10.1111/fcp.12561"], "Journal": {"ISSN": "1472-8206", "JournalIssue": {"Volume": "35", "Issue": "1", "PubDate": {"Year": "2021", "Month": "Feb"}}, "Title": "Fundamental & clinical pharmacology", "ISOAbbreviation": "Fundam Clin Pharmacol"}, "ArticleTitle": "Progress on ocular siRNA gene-silencing therapy and drug delivery systems.", "Pagination": {"StartPage": "4", "EndPage": "24", "MedlinePgn": "4-24"}, "Abstract": {"AbstractText": ["Age-related macular degeneration (AMD) and glaucoma are global ocular diseases with high blindness rate. RNA interference (RNAi) is being increasingly used in the treatment of these disorders with siRNA drugs, bevasiranib, AGN211745 and PF-04523655 for AMD, and SYL040012 and QPI-1007 for glaucoma. Administration routes and vectors of gene drugs affect their therapeutic effect. Compared with the non-viral vectors, viral vectors have limited payload capacity and potential immunogenicity. This review summarizes the progress of the ocular siRNA gene-silencing therapy by focusing on siRNA drugs for AMD and glaucoma already used in clinical research, the main routes of drug delivery and the non-viral vectors for siRNA drugs."], "CopyrightInformation": "\u00a9 2020 Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et de Th\u00e9rapeutique."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, No.1, DongQing Road, Guiyang, 550014, People's Republic of China."}, {"Identifier": [], "Affiliation": "Department of Pharmacy, China Pharmaceutical University, No.639, Longmian Avenue, Nanjing, 211198, People's Republic of China."}], "LastName": "Jiang", "ForeName": "Jinjin", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, No.1, DongQing Road, Guiyang, 550014, People's Republic of China."}, {"Identifier": [], "Affiliation": "Department of Pharmacy, China Pharmaceutical University, No.639, Longmian Avenue, Nanjing, 211198, People's Republic of China."}], "LastName": "Zhang", "ForeName": "Xinru", "Initials": "X"}, {"Identifier": ["0000-0001-9915-5499"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, No.1, DongQing Road, Guiyang, 550014, People's Republic of China."}, {"Identifier": [], "Affiliation": "Department of Pharmacy, China Pharmaceutical University, No.639, Longmian Avenue, Nanjing, 211198, People's Republic of China."}], "LastName": "Tang", "ForeName": "Yue", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, China Pharmaceutical University, No.639, Longmian Avenue, Nanjing, 211198, People's Republic of China."}], "LastName": "Li", "ForeName": "Shuhan", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, China Pharmaceutical University, No.639, Longmian Avenue, Nanjing, 211198, People's Republic of China."}], "LastName": "Chen", "ForeName": "Jing", "Initials": "J"}], "GrantList": [{"GrantID": "[2017]5101", "Agency": "Guizhou Science and Technology Platform Talents", "Country": ""}, {"GrantID": "FAMP201805K", "Agency": "State Key Laboratory of Functions and Applications of Medicinal Plants of Guizhou Medicinal University", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Fundam Clin Pharmacol", "NlmUniqueID": "8710411", "ISSNLinking": "0767-3981"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "RNA, Small Interfering"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Blood-Retinal Barrier"}, {"QualifierName": [], "DescriptorName": "Drug Delivery Systems"}, {"QualifierName": [], "DescriptorName": "Gene Silencing"}, {"QualifierName": ["methods"], "DescriptorName": "Genetic Therapy"}, {"QualifierName": ["therapy"], "DescriptorName": "Glaucoma"}, {"QualifierName": ["therapy"], "DescriptorName": "Macular Degeneration"}, {"QualifierName": ["administration & dosage", "genetics"], "DescriptorName": "RNA, Small Interfering"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Golestaneh N., Chu Y., Cheng S.K., Cao H., Poliakov E., Berinstein D.M. Repressed sirt1/pgc-1\u03b1 pathway and mitochondrial disintegration in ipsc-derived rpe disease model of age-related macular degeneration. J. Transl. Med. (2016) 14 1-17."}, {"Citation": "Lee Y.W., Hwang Y.E., Lee J.Y., Sohn J.H., Sung B.H., Kim S.C. VEGF siRNA delivery by a cancer-specific cell-penetrating peptide. J. Microbiol. Biotechnol. (2018) 28 367-374."}, {"Citation": "Pittella F., Miyata K., Maeda Y. et al. Pancreatic cancer therapy by systemic administration of VEGF siRNA contained in calcium phosphate/charge-conversional polymer hybrid nanoparticles. J. Control Release (2012) 161 868-874."}, {"Citation": "Cai X., Zhu H., Zhang Y., Gu Z. Highly efficient and safe delivery of VEGF siRNA by bioreducible fluorinated peptide dendrimers for cancer therapy. ACS Appl. Mater. Interfaces (2017) 9 9402-9415."}, {"Citation": "Nimesh S., Chandra R. Polyethylenimine nanoparticles as an efficient in vitro siRNA delivery system. Eur. J. Pharm. Biopharm. (2009) 73 43-49."}, {"Citation": "Vicentini F.T., Borgheti-Cardoso L.N., Depieri L.V. et al. Delivery systems and local administration routes for therapeutic siRNA. Pharm. Res. (2013) 30 915-931."}, {"Citation": "Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. (2006) 58 1131-1135."}, {"Citation": "Geroski D.H., Edelhauser H.F. Transscleral drug delivery for posterior segment disease. Adv. Drug Deliv. Rev. (2001) 52 37-48."}, {"Citation": "Hornof M., Toropainen E., Urtti A. Cell culture models of the ocular barriers. Eur. J. Pharm. Biopharm. (2005) 60 207-225."}, {"Citation": "Barar J., Asadi M., Mortazavi-Tabatabaei S.A., Omidi Y. Ocular drug delivery; impact of in vitro cell culture models. J. Ophthalmic Vis. Res. (2009) 4 238-252."}, {"Citation": "Em A., Vellonen K-S, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv. Drug Deliv. Rev. (2006) 58 1136-1163."}, {"Citation": "Cunha-Vaz J.G. The blood-ocular barriers: past, present, and future. Doc. Ophthalmol. (1997) 93 149-157."}, {"Citation": "Duvvuri S., Majumdar S., Mitra A.K. Drug delivery to the retina. Expert Opin. Biol. Ther. (2003) 3 45-56."}, {"Citation": "Madni A., Rahem M.A., Tahir N. et al. Non-invasive strategies for targeting the posterior segment of eye. Int. J. Pharm. (2017) 530 326-345."}, {"Citation": "Hsu K., Gause S., Chauhan A. Review of ophthalmic drug delivery by contact lenses. J. Drug Deliv. Sci. Technol. (2014) 24 123-135."}, {"Citation": "Behar-Cohen F. Drug delivery to the eye: current trends and future perspectives. Ther. Deliv. (2012) 3 1135-1137."}, {"Citation": "Sepahvandi A., Eskandari M., Moztarzadeh F. Drug delivery systems to the posterior segment of the eye: implants and nanoparticles. Bionanoscience (2016) 6 276-283."}, {"Citation": "Solin\u00eds M.\u00c1., del Pozo-Rodr\u00edguez A., Apaolaza P.S., Rodr\u00edguez-Gasc\u00f3n A. Treatment of ocular disorders by gene therapy. Eur. J. Pharm. Biopharm. (2015) 95 331-342."}, {"Citation": "Eljarrat-Binstock E., Pe\u2019er J., Domb A.J. New techniques for drug delivery to the posterior eye segment. Pharm. Res. (2010) 27 530-543."}, {"Citation": "Loftsson T., Stef\u00e1nsson E. Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye. Int. J. Pharm. (2017) 531 413-423."}, {"Citation": "Rupenthal I.D., O\u2019Rourke M. Ocular drug delivery-eye on innovation. Drug Deliv. Transl. Res. (2016) 6 631-633."}, {"Citation": "Bloquel C., Bourges J.l., Touchard E., Berdugo M., BenEzra D., Behar-Cohen F. Non-viral ocular gene therapy: Potential ocular therapeutic avenues. Adv. Drug Deliv. Rev. (2006) 58 1224-1242."}, {"Citation": "Kaji H., Nagai N., Nishizawa M., Abe T. Drug delivery devices for retinal diseases. Adv. Drug Deliv. Rev. (2018) 128 148-157."}, {"Citation": "Burns E., Mulley G.P. Practical problems with eye-drops among elderly ophthalmology outpatients. Age Ageing (1992) 21 168-170."}, {"Citation": "Kaur I.P., Smitha R. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev. Ind. Pharm. (2002) 28 353-369."}, {"Citation": "Chen W., Li Z., Hu J. et al. Corneal alternations induced by topical application of benzalkonium chloride in rabbit. PLoS ONE (2011) 6 e26103."}, {"Citation": "Souza J.G., Dias K., Pereira T.A., Bernardi D.S., Lopez R.F.V. Topical delivery of ocular therapeutics: Carrier systems and physical methods. J. Pharm. Pharmacol. (2014) 66 507-530."}, {"Citation": "Mullin L.B., Phillips L.C, Dayton P.A. Nanoparticle delivery enhancement with acoustically activated microbubbles. IEEE Trans. Ultrason. Ferroelectr. Freq. Control (2013) 60 65-77."}, {"Citation": "Kowalczuk L., Boudinet M., El Sanharawi M. et al. In vivo gene transfer into the ocular ciliary muscle mediated by ultrasound and microbubbles. Ultrasound Med. Biol. (2011) 37 1814-1827."}, {"Citation": "Ciolino J.B., ., Dohlman C.H., Kohane D.S. Contact lenses for drug delivery. Semin. Ophthalmol. (2009) 24 156-160."}, {"Citation": "Puras G., Zarate J., D\u00edaz-Tahoces A., Avil\u00e9s-Trigueros M., Fern\u00e1ndez E., Pedraz J.l. Oligochitosan polyplexes as carriers for retinal gene delivery. Eur. J. Pharm. Sci. (2013) 48 323-331."}, {"Citation": "Peynshaert K., Devoldere J., Minnaert A.-K., De Smedt S.C., Remaut K. Morphology and composition of the inner limiting membrane: species-specific variations and relevance toward drug delivery research. Curr. Eye Res. (2019) 44 465-475."}, {"Citation": "Pitk\u00e4nen L., Ruponen M., Nieminen J., Urtti A. Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharm. Res. (2003) 20 576-583."}, {"Citation": "Peeters L., Sanders N.N., Braeckmans K. et al. Vitreous: a barrier to nonviral ocular gene therapy. Investig. Ophthalmol. Vis. Sci. (2005) 46 3553-3561."}, {"Citation": "Huang X., Chau Y. Investigating impacts of surface charge on intraocular distribution of intravitreal lipid nanoparticles. Exp. Eye Res. (2019) 186 107711."}, {"Citation": "Tamboli V., Mishra G.P., Mitra A.K. Polymeric vectors for ocular gene delivery. Ther Deliv (2011) 2 523-536."}, {"Citation": "Avery R.L., Castellarin A.A., Steinle N.C. et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular amd. Br. J. Ophthalmol. (2014) 98 1636-1641."}, {"Citation": "Mahnama A., Nourbakhsh A., Ghorbaniasl G. A survey on the applications of implantable micropump systems in drug delivery. Curr. Drug Deliv. (2014) 11 123-131."}, {"Citation": "Peng Y., Tang L., Zhou Y. Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases. Ophthalmic Res. (2017) 58 217-226."}, {"Citation": "Chang J.N. Recent advances in ophthalmic drug delivery. Handb. Non Invasive Drug Deliv. Syst. (2010) 165-192."}, {"Citation": "Bourges J.L., Bloquel C., Thomas A. et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv. Drug Deliv. Rev. (2006) 58 1182-1202."}, {"Citation": "Kaur I.P., Kakkar S. Nanotherapy for posterior eye diseases. J. Control Release (2014) 193 100-112."}, {"Citation": "Gaudana R., Ananthula H.K., Parenky A., Mitra A.K. Ocular drug delivery. AAPS J. (2010) 12 348-360."}, {"Citation": "Kim J.H., Kim J.H., Kim K.-W., Kim M.H., Yu Y.S. Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity. Nanotechnology (2009) 20 505101."}, {"Citation": "Hyttinen J.M.T., Viiri J., Kaarniranta K., B\u0142asiak J. Mitochondrial quality control in AMD: does mitophagy play a pivotal role? Cell. Mol. Life Sci. (2018) 75 2991-3008."}, {"Citation": "Golestaneh N., Chu Y., Xiao Y.-Y., Stoleru G.L., Theos A.C. Dysfunctional autophagy in RPE, a contributing factor in age-related macular degeneration. Cell Death Dis. (2017) 8 e2537."}, {"Citation": "Jarrett S.G., Boulton M.E. Consequences of oxidative stress in age-related macular degeneration. Mol. Aspects Med. (2012) 33 399-417."}, {"Citation": "Kaarniranta K., Salminen A., Eskelinen E.-L., Kopitz J. Heat shock proteins as gatekeepers of proteolytic pathways-Implications for age-related macular degeneration (AMD). Ageing Res. Rev. (2009) 8 128-139."}, {"Citation": "Kinnunen K., Petrovski G., Moe M.C., Berta A., Kaarniranta K. Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration. Acta Ophthalmol. (2012) 90 299-309."}, {"Citation": "Mettu P.S., Wielgus A.R., Ong S.S., Cousins S.W. Retinal pigment epithelium response to oxidant injury in the pathogenesis of early age-related macular degeneration. Mol. Aspects Med. (2012) 33 376-398."}, {"Citation": "Tuo J., , Grob S., Zhang K., Chan C.-C. Genetics of immunological and inflammatory components in age-related macular degeneration. Ocul. Immunol. Inflamm. (2012) 20 27-36."}, {"Citation": "Singerman L. Combination therapy using the small interfering RNA bevasiranib. Retina (2009) 29 49-50."}, {"Citation": "Spilsbury K., Garrett K.L., Shen W.-Y., Constable I.J., Rakoczy P.E. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am. J. Pathol. (2000) 157 135-144."}, {"Citation": "Nguyen Q.D., Schachar R.A., Nduaka C.I. et al. Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye (2012) 26 1099-1105."}, {"Citation": "Moore N.A., Bracha P., Hussain R.M., Morral N., Ciulla T.A. Gene therapy for age-related macular degeneration. Expert Opin. Biol. Ther. (2017) 17 1235-1244."}, {"Citation": "Wells J.A., Murthy R., Chibber R. et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br. J. Ophthalmol. (1996) 80 363-366."}, {"Citation": "Kliffen M., Sharma H.S., Mooy C.M., Kerkvliet S., de Jong P.T.V.M. Increased expression of angiogenic growth factors in age-related maculopathy. Br. J. Ophthalmol. (1997) 81 154-162."}, {"Citation": "Garba A.O., Mousa S.A. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol. Eye Dis. (2010) 2 OED.S4878."}, {"Citation": "Dejneka N.S., Wan S., Bond O.S., Kornbrust D.J., Reich S.J. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol. Vis. (2008) 14 997-1005."}, {"Citation": "Tolentino M.J., Brucker A.J., Fosnot J. et al. Intravitreal injection of vascular endothelial growth factor small interfering rna inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina (2004) 24 132-138."}, {"Citation": "Kwak N., Okamoto N., Wood J.M., Campochiaro P.A. VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. (2000) 41 3158-3164."}, {"Citation": "Ferrara N., Carver-Moore K., Chen H. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (1996) 380 439-442."}, {"Citation": "Shen J., Samul R., Silva R.l et al.Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. (2006) 13 225-234."}, {"Citation": "Ferrara N., Gerber H.-P., LeCouter J. The biology of VEGF and its receptors. Nat Med (2003) 9 669-676."}, {"Citation": "Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. BMB Rep. (2006) 39 469-478."}, {"Citation": "Kaiser P.K., Symons R.C.A., Shah S.M. et al. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am. J. Ophthalmol. (2010) 150 33-39.e2."}, {"Citation": "Corradetti M.N., Inoki K., Guan K.-L. The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J. Biol. Chem. (2005) 280 9769-9772."}, {"Citation": "Shoshani T., Faerman A., Mett I. et al. Identi cation of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol. Cell. Biol. (2002) 22 2283-2293."}, {"Citation": "Brafman A., Mett I., Shafir M. et al. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Investig. Ophthalmol. Vis. Sci. (2004) 45 3796-3805."}, {"Citation": "Rittenhouse K.D., Johnson T.R., Vicini P. et al. RTP801 gene expression is differentially upregulated in retinopathy and is silenced by PF-04523655, a 19-mer siRNA directed against RTP801. Investig. Ophthalmol. Vis. Sci. (2013) 55 1232-1240."}, {"Citation": "Glaucoma C.J. A disease of early cellular senescence. Investig. Ophthalmol. Vis. Sci. (2013) 54(14) ORSF60."}, {"Citation": "Goel M., Picciani R.G., Lee R.K., Bhattacharya S.K. Aqueous humor dynamics: a review. Open Ophthalmol. J. (2010) 4 52-59."}, {"Citation": "Mart\u00ednez T., Gonz\u00e1lez M.V., Roehl I., Wright N., Pa\u00f1eda C., Jim\u00e9nez A.I. In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol. Ther. (2014) 22 81-91."}, {"Citation": "Wax M.B., Molinoff P. Distribution and properties of beta adrenergic receptors in human iris/ciliar body. Invest. Ophthalmol. Vis. Sci. (1987) 28 420-430."}, {"Citation": "Elena P.P., Denis P., Kosina-boix M., Saraux H., Lapalus P. Beta adrenergic binding sites in the human eye: an autoradiographic study. J. Ocul. Pharmacol. (1990) 6 143-149."}, {"Citation": "Trope G.E., Clark B. Beta adrenergic receptors in pigmented ciliary processes. Br. J. Ophthalmol. (1982) 66 788-792."}, {"Citation": "Moreno-Monta\u00f1\u00e9s J., S\u00e1daba B., Ruz V. et al. Phase I clinical trial of SYL040012, a small interfering RNA targeting \u03b2-adrenergic receptor 2, for lowering intraocular pressure. Mol. Ther. (2014) 22 226-232."}, {"Citation": "Gonzalez V., Palumaa K., Turman K. et al. Phase 2 of bamosiran (SYL040012), a novel RNAi based compound for the treatment of increased intraocular pressure associated to glaucoma. Investig. Ophthalmol. Vis. Sci. 2014 55 564."}, {"Citation": "Gonzalez V., Moreno-Montanes J., Oll M. et al. Results of phase IIB SYLTAG clinical trial with bamosiran in patients with glaucoma. Assoc. Res. Vis. Ophthalmol. (2016) 57 3023."}, {"Citation": "Levin L.A. Axonal loss and neuroprotection in optic neuropathies. Can. J. Ophthalmol. (2007) 42 403-408."}, {"Citation": "Schmidt K.-G., Bergert H., Funk R.H. Neurodegenerative diseases of the retina and potential for protection and recovery. Curr. Neuropharmacol. (2008) 6 164-178."}, {"Citation": "Ahmed Z., Kalinski H., Berry M. et al. Ocular neuroprotection by siRNA targeting caspase-2. Cell Death Dis. (2011) 2 e173."}, {"Citation": "Titze-de-Almeida R., David C., Titze-de-Almeida S.S.The Race of 10 synthetic RNAi-based drugs to the pharmaceutical market. Pharm. Res. (2017) 34 1339-1363."}, {"Citation": "Solano E.C.R., Kornbrust D.J., Beaudry A., Foy J.W.-D., Schneider D.J., Thompson J.D. Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. (2014) 24 258-266."}, {"Citation": "Oliveira A.V., Rosa da Costa A.M., Silva G.A. Non-viral strategies for ocular gene delivery. Mater. Sci. Eng. C (2017) 77 1275-1289."}, {"Citation": "del Amo E.M., Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov. Today (2008) 13 135-143."}, {"Citation": "Foldvari M., Chen D.W., Nafissi N., Calderon D., Narsineni L., Rafiee A. Non-viral gene therapy: gains and challenges of non-invasive administration methods. J. Control Release (2016) 240 165-190."}, {"Citation": "Tamboli V., Mishra G.P., Mitra A.K. Polymeric vectors for ocular gene delivery. Ther. Deliv. (2011) 2 523-536."}, {"Citation": "Farra R., Maruna M., Perrone F. et al. Strategies for delivery of siRNAs to ovarian cancer cells. Pharmaceutics (2019) 11 547."}, {"Citation": "Aleku M., Schulz P., Keil O. et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. (2008) 68 9788-9798."}, {"Citation": "Santel A., Aleku M., Keil O. et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. (2006) 13 1222-1234."}, {"Citation": "Schultheis B., Strumberg D., Santel A. et al. First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J. Clin. Oncol. (2014) 32 4141-4148."}, {"Citation": "Weng Y., Xiao H., Zhang J., Liang X.-J., Huang Y. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol. Adv. (2019) 37 801-825."}, {"Citation": "Kristen A.V., Ajroud-Driss S., Concei\u00e7\u00e3o I., Gorevic P., Kyriakides T., Obici L. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener. Dis. Manag. (2019) 9 5-23."}, {"Citation": "Zhang X., Goel V., Attarwala H., Sweetser M.T., Clausen V.A., Robbie G.J. Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. J. Clin. Pharmacol. (2020) 60 37-49."}, {"Citation": "Coelho T., Adams D., Silva A. et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. (2013) 369 819-829."}, {"Citation": "Suhr O.B., Coelho T., Buades J. et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J. Rare Dis. (2015) 10 1-9."}, {"Citation": "Gonz\u00e1lez-Duarte A., Berk J.L., Quan D. et al. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. J. Neurol. (2020) 267(3) 703-712."}, {"Citation": "Xia J., Chen L., Chen J. et al. Hydrophobic polyphenylalanine-grafted hyperbranched polyethylenimine and its in vitro gene transfection. Macromol. Biosci. (2011) 11 211-218."}, {"Citation": "Peng Q., Hu C., Cheng J., Zhong Z., Zhuo R. Influence of disulfide density and molecular weight on disulfide cross-linked polyethylenimine as gene vectors. Bioconjug. Chem. (2009) 20 340-346."}, {"Citation": "Chen J., Jiao Z., Lin L. et al. Polylysine-modified polyethylenimines as siRNA carriers for effective tumor treatment. Chinese J. Polym. Sci. (2015) 33 830-837."}, {"Citation": "Han H., Son S., Son S. et al. Reducible polyethylenimine nanoparticles for efficient siRNA delivery in corneal neovascularization therapy. Macromol. Biosci. (2016) 16 1583-1597."}, {"Citation": "Watanabe K., Harada-Shiba M., Suzuki A. et al. In vivo siRNA delivery with dendritic poly(l-lysine) for the treatment of hypercholesterolemia. Mol. Biosyst. (2009) 5 1306-1310."}, {"Citation": "Park T.G., Jeong J., Kim S. Current status of polymeric gene delivery systems. Adv. Drug Deliv. Rev. (2006) 58 467-486."}, {"Citation": "Kozielski K.L., Tzeng S.Y., Green J.J. Bioengineered nanoparticles for siRNA delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. (2013) 5 449-468."}, {"Citation": "Lim Y.B., Han S.O., Kong H.U. et al. Biodegradable polyester, poly[\u03b1-(4-aminobutyl)-l-glycolic acid], as a non-toxic gene carrier. Pharm. Res. (2000) 17 811-816."}, {"Citation": "Liu P., Yu H., Sun Y., Zhu M., Duan Y. A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery. Biomaterials (2012) 33 4403-4412."}, {"Citation": "Cheng Y., Xu Z., Ma M., Xu T. Dendrimers as drug carriers: applications in different routes of drug administration. J. Pharm. Sci. (2008) 97 123-143."}, {"Citation": "Liu X., Rocchi P., Peng L. Dendrimers as non-viral vectors for siRNA delivery. New J. Chem. (2012) 36 256-263."}, {"Citation": "Chaplot S.P., Rupenthal I.D. Dendrimers for gene delivery - A potential approach for ocular therapy? J. Pharm. Pharmacol. (2014) 66 542-556."}, {"Citation": "Rodr\u00edguez Villanueva J., Navarro M.G., Rodr\u00edguez Villanueva L. Dendrimers as a promising tool in ocular therapeutics: latest advances and perspectives. Int J Pharm (2016) 511 359-366."}, {"Citation": "Wu J., Huang W., He Z. Dendrimers as carriers for siRNA delivery and gene silencing: a review. Sci. World J. (2013) 2013 1-16."}, {"Citation": "Deng J., Li N., Mai K., Yang C., Yan L., Zhang L.-M. Star-shaped polymers consisting of a \u03b2-cyclodextrin core and poly(amidoamine) dendron arms: Binding and release studies with methotrexate and siRNA. J. Mater. Chem. (2011) 21 5273-5281."}, {"Citation": "Hanurry E.Y., Hsu W.-H., Darge H.F. et al. In vitro siRNA delivery via diethylenetriamine- and tetraethylenepentamine-modified carboxyl group-terminated Poly(amido)amine generation 4.5 dendrimers. Mater. Sci. Eng. C (2020) 106 110245."}, {"Citation": "Arranz-Romera A., Davis B.M., Bravo-Osuna I. et al. Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma. J. Control Release (2018) 2019 26-38."}, {"Citation": "Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Pr\u00e9at V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control Release (2012) 161 505-522."}, {"Citation": "Subrizi A., del Amo E.M., Korzhikov-Vlakh V., Tennikova T., Ruponen M., Urtti A. Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties. Drug Discov. Today (2019) 24 1446-1457."}, {"Citation": "Makadia H.K., Siegel S.J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel) (2011) 3 1377-1397."}, {"Citation": "Murata N., Takashima Y., Toyoshima K., Yamamoto M., Okada H. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J. Control Release (2008) 126 246-254."}, {"Citation": "Wang H., Zhao P., Su W. et al.PLGA/polymeric liposome for targeted drug and gene co-delivery. Biomaterials (2010) 31 8741-8748."}, {"Citation": "Mintzer M.A., Simanek E.E. Nonviral vectors for gene delivery. Chem. Rev. (2009) 979 259-302."}, {"Citation": "Kim M.G., Jo S.D., Yhee J.Y. et al. Synergistic anti-tumor effects of bevacizumab and tumor targeted polymerized VEGF siRNA nanoparticles. Biochem. Biophys. Res. Commun. (2017) 489 35-41."}, {"Citation": "De La Fuente M., Seijo B., Alonso M.J. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Investig. Ophthalmol. Vis. Sci. (2008) 49 2016-2024."}, {"Citation": "St George J.A. Gene therapy progress and prospects: adenoviral vectors. Gene Ther (2003) 10 1135-1141."}, {"Citation": "Ryoo N.K., Lee J., Lee H. et al.Therapeutic effects of a novel siRNA-based anti-VEGF (siVEGF) nanoball for the treatment of choroidal neovascularization. Nanoscale (2017) 9 15461-15469."}, {"Citation": "Qin Y., Tian Y., Liu Y. et al. Hyaluronic acid-modified cationic niosomes for ocular gene delivery: improving transfection efficiency in retinal pigment epithelium. J. Pharm. Pharmacol. (2018) 70 1139-1151."}, {"Citation": "Johnson L.N., Cashman S.M., Kumar-Singh R. Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea. Mol Ther (2008) 16 107-114."}, {"Citation": "Dillinger A.E., Guter M., Froemel F. et al.Intracameral delivery of layer-by-layer coated siRNA nanoparticles for glaucoma therapy. Small (2018) 14 1-15."}], "Title": "REFERENCES"}], "History": [{"Year": "2019", "Month": "8", "Day": "23"}, {"Year": "2020", "Month": "3", "Day": "24"}, {"Year": "2020", "Month": "4", "Day": "10"}, {"Year": "2020", "Month": "4", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "10", "Day": "5", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "4", "Day": "17", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["32298491", "10.1111/fcp.12561"]}}]}